Enoxaparin dosing after cesarean delivery in morbidly obese women

Obstetrics and Gynecology

Volumn 125, Issue 6, 2015, Pages 1371-1376

  Overcash, Rachael T ^a   Somers, Alicia T ^a   Lacoursiere, D Yvette ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEMOGLOBIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ADULT; ARTICLE; BODY MASS; CESAREAN SECTION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMATOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; MORBID OBESITY; OPERATIVE BLOOD LOSS; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTE; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; ADVERSE EFFECTS; BLOOD; BODY WEIGHT; CHEMICALLY INDUCED; COMPLICATION; DOSE CALCULATION; DRUG MONITORING; PREGNANCY; PREGNANCY COMPLICATION; VULVA DISEASE; YOUNG ADULT;

ADULT; ANTICOAGULANTS; BODY MASS INDEX; BODY WEIGHT; CESAREAN SECTION; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; ENOXAPARIN; FACTOR XA INHIBITORS; FEMALE; HEMATOMA; HUMANS; OBESITY, MORBID; PREGNANCY; PREGNANCY COMPLICATIONS; PROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM; VULVAR DISEASES; YOUNG ADULT;

EID: 84929881387     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000873     Document Type: Article

References (22)

1. Prevention of deep vein thrombosis and pulmonary embolism. ACOG Practice Bulletin No. 84. American College of Obstetricians and Gynecologists. Obstet Gynecol 2007;110: 429-40.
2. WHO, UNICEF, UNFPA, The World Bank. Trends in maternal mortality: 1990 to 2010. WHO, UNICEF, UNFPA and The World Bank estimates. Geneva (Switzerland): World Health Organization; 2012.
3. Robinson HE, O'Connell CM,Joseph KS, McLeod NL. Maternal outcomes in pregnancies complicated by obesity. Obstet Gynecol 2005;106:1357-64.
4. Obesity in pregnancy. Committee Opinion No. 549. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013;121:213-7.
5. Weiss JL, Malon FD, Emig D, Ball RH, Nyberg DA, Comstock CH, et al. Obesity, obstetric complications and cesarean delivery rate-a population-based screening study. Am J Obstet Gynecol 2004;190:1091-7.
6. Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. RCOG green-top guideline no. 37a. London (UK): Royal College of Obstetricians and Gynaecologists; 2009.
7. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(suppl):e691S-736S.
8. Greer IA, Nelson-Piercy C. Low molecular weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systemic review of safety and efficacy. Blood 2005;106:401-7.
9. Sanson BJ, Lensing AW, Prins MH, GinsbergJS, Barkagan ZS, Lavenne-Pardonge E, et al. Safety of low-molecular weight heparin in pregnancy: a systemic review. Thromb Haemost 1999; 81:668-72.
10. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, ArcelusJI, Heit JA, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis. 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(suppl): e227S-77S.
11. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126 (suppl):627S-44S.
12. Borkgre-Okonek MJ, Hart RW, Pantano JE, Rantis JC, Guske PJ, Kane JM Jr, et al. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg Obes Relat Dis 2008;4: 625-31.
13. Ludwig KP, Simon HJ, Mone M, Barton RG, Kimball EJ. Implementation of an enoxaparin protocol for venous thrombo-embolism prophylaxis in obese surgical intensive care unit patients. Ann Pharmacother 2011;45:1356-62.
14. Gyamfi C, Cohen R, Desancho MT, Gaddipati S. Prophylactic dosing adjustment in pregnancy based upon measurements of anti-factor Xa levels. J Matern Fetal Neonatal Med 2005;18: 329-31.
15. Friedrich E, Hameed AB. Fluctuations in anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy. J Perinatol 2010;30:253-7.
16. Simone EP, Madan AK, Tichandky DS, Kuhl DA, Lee MD. Comparison of two low-molecular weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery. Surg Endosc 2008;22:2392-5.
17. Rondina MT, Wheeler M, Rodgers GM, Draper L, Pendleton RC. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients. Thromb Res 2010;125:220-3.
18. Hiscock RJ, Casey E, Simmons SW, Walker SP, Newell PA. Peak plasma anti-Xa levels after the first and third dose of enoxaparin in women receiving weight-based thromboprophy-laxis following caesarean section: a prospective cohort study. Int J Obstet Anesth 2013;22:280-8.
19. Bergqvist D, Lowe G, Berstad A, Haas S, Hirsh J, Lassen MR, et al. Prevention of venous thromboembolism after surgery: a review of enoxaparin. Br J Surg 1992;79:495-8.
20. Samama M, Cohen A, Darmon J, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793-800.
21. Freeman AL, Pendleton RC, Rondina MT. Prevention of venous thromboembolism in obesity. Expert Rev Cardiovasc Ther 2010;8:1711-21.
22. Thromboembolism in pregnancy. Practice Bulletin No. 123. American College of Obstetricians and Gynecologists. Obstet Gynecol 2011;118:718-29.